drug induced liver injury blog posts

03 November, 2017

6 crucial facts about DILI you ought to know

By Guy Webber

Drug induced liver injury (DILI) is a major cause of safety-related drug withdrawal and black box warnings post-market. It is also a major cause of drug attrition during development. One of the main concerns about DILI is that it is often undetected until clinical development and/or post-market approval, when the molecule is exposed to larger populations. 

So what do you need to know about DILI that will help you to reduce the risk of hepatotoxicity in humans?  Here are six facts to keep in mind.

+ Read more
 

04 October, 2017

How in vitro assays and drug metabolism are being used to de-risk drug development

By Guy Webber

If all molecules in discovery and development were added together over recent years and compared to the number of successful drug approvals each year, the ratio is (approximately) 10,000:1. In other words, for every 10,000 molecules entering drug discovery, 9,999 will fail during some stage of the development process. Evidently, developing a molecule that has a desired, efficacious yet safe effect in humans is a remarkable achievement considering the lengthy, complex and expensive process.

+ Read more